BioMaxima SA

BioMaxima's capital structure is characterized by a debt-to-equity ratio of 0.3, indicating a relatively conservative leverage profile compared to the industry median of 0.5. The company's liquidity position is constrained, with cash and equivalents of PLN 1.74 million and a negative net cash position after subtracting total debt. The enterprise value to revenue ratio of 0.99 suggests a low valuation multiple, potentially reflecting market skepticism about near-term growth or margin expansion. Profitability metrics show mixed performance. The company's operating cash flow of PLN 3.37 million is positive but modest, and its return on invested capital (ROIC) is not disclosed. Given the industry's preference for gross margins and EBITDA margins as key performance indicators, BioMaxima's lack of disclosed margin data limits direct comparison to the cohort median of 55% gross margin and 18% EBITDA margin. The company's revenue of PLN 62.87 million is concentrated in Poland and select European markets, with no disclosed segment breakdown. Geographically, BioMaxima's revenue is heavily concentrated in Poland, with additional exposure to Lithuania, Latvia, Romania, and France. The absence of a detailed geographic revenue breakdown in the input data prevents a precise assessment of diversification risk. However, the company's limited international footprint suggests vulnerability to domestic economic or regulatory shifts. Growth trajectory appears modest. The company's current fiscal year outlook does not include specific revenue growth targets, and historical revenue data is not provided. The absence of disclosed capex plans or R&D investment percentages makes it difficult to assess long-term growth drivers. The company's market cap of PLN 49.4 million is significantly lower than the industry median, suggesting limited market capitalization and potential for volatility. Risk factors include medium liquidity risk due to the negative net cash position and a debt-to-equity ratio that, while low, could increase if the company pursues expansion. The risk assessment flags net cash as negative after subtracting total debt, and dilution risk is currently low. No recent filings or transcripts are provided to assess management commentary or strategic shifts. Recent events are not detailed in the input data, but the company's 2014 merger with its subsidiary Cebo Sp z o o suggests a history of consolidation. The absence of recent earnings calls, regulatory filings, or press releases limits insight into current strategic direction or operational performance.